abiraterone has been researched along with Cardiovascular Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engel, M; Hartmann, RW; Hu, Q; Pinto-Bazurco Mendieta, MA | 1 |
| Bennett, CL; Carson, KR; Drake, BF; Eisen, SA; Knoche, EM; Luo, S; Reimers, MA; Sanfilippo, KM; Schoen, MW; Whitmer, AL; Yan, Y | 1 |
| Chang, CF; Chang, KC; Chang, PH; Chang, YH; Chen, HK; Chen, HY; Chuang, CK; Hsieh, CH; Huang, WK; Kuan, FC; Kuo, YC; Lai, EC; Lin, PH; Lin, YC; Pang, ST; Sheng, TW; Su, PJ; Su, YL; Tsan, DL; Wang, YL; Yu, KJ; Yu, SM | 1 |
| Garmo, H; Gedeborg, R; George, G; Lissbrant, IF; Stattin, P; Styrke, J; Van Hemelrijck, M; Vikman, H | 1 |
| Addison, D; Baliga, R; Calaway, AC; Campbell, CM; Challa, AA; Cullen, J; Desai, N; Deswal, A; Garcia, J; Guha, A; Kutty, S; Vallakati, A; Weintraub, NL | 1 |
| Artibani, W; Bimbatti, D; Bria, E; Brunelli, M; Ciccarese, C; Fantinel, E; Iacovelli, R; Mazzarotto, R; Muraglia, A; Porcaro, AB; Romano, M; Siracusano, S; Tortora, G | 1 |
| Raghavan, D; Shepard, DR | 1 |
| Schmidt, C | 1 |
3 review(s) available for abiraterone and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular Toxicities of Androgen Deprivation Therapy.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Cardiotoxicity; Cardiovascular Diseases; COVID-19; Disease Susceptibility; Gonadotropin-Releasing Hormone; Health Status Disparities; Humans; Male; Prostatic Neoplasms; SARS-CoV-2 | 2021 |
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.
Topics: Androstenes; Benzamides; Cardiovascular Diseases; Disease-Free Survival; Humans; Hypertension; Incidence; Male; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
Innovations in the systemic therapy of prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Drugs, Investigational; Humans; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis | 2010 |
5 other study(ies) available for abiraterone and Cardiovascular Diseases
| Article | Year |
|---|---|
Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Cell Line; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; Male; Models, Molecular; Naphthalenes; Prostatic Neoplasms; Pyridines; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase | 2013 |
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.
Topics: Abiraterone Acetate; Cardiovascular Diseases; Diabetes Mellitus; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Veterans | 2023 |
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Cardiovascular Diseases; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cardiovascular Diseases; Cohort Studies; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Sweden | 2021 |
Abiraterone and MVD3100 take androgen deprivation to a new level.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Dihydrotestosterone; Drug Approval; Gonadotropin-Releasing Hormone; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Testosterone; Time Factors; United States; United States Food and Drug Administration | 2011 |